S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: Wall Street extends its rally and closes at highest level since March 2022
Energy traders: A rebound is coming
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kroger shares are begging to be bought 
Dallas Mavericks purchase turns LVS stock into a cheaper bet
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Behind the tech boom: Big price leaders selectively laying off
Earnings propel Crowdstrike, cybersecurity sector, to new highs

ORIC Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ORIC)

$8.27
+0.37 (+4.68%)
(As of 12/1/2023 ET)
Compare
Today's Range
$7.65
$8.30
50-Day Range
$5.41
$8.27
52-Week Range
$2.91
$9.79
Volume
406,163 shs
Average Volume
339,532 shs
Market Capitalization
$451.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.29

ORIC Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
96.9% Upside
$16.29 Price Target
Short Interest
Bearish
28.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.96) to ($2.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

543rd out of 950 stocks

Pharmaceutical Preparations Industry

257th out of 437 stocks


ORIC stock logo

About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Stock Price History

ORIC Stock News Headlines

ORIC Pharmaceuticals Inc ORIC
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
ORIC Pharmaceuticals GAAP EPS of -$0.44
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Analyst Expectations for ORIC Pharmaceuticals's Future
Oric Pharmaceuticals (ORIC) Receives a Buy from Robert W. Baird
Why Oric Pharmaceuticals Stock Is Shooting Higher Today
Why Shares of Oric Pharmaceuticals Jumped Monday
See More Headlines
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORIC
Fax
N/A
Employees
93
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.29
High Stock Price Target
$27.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+96.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-89,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.54 per share

Miscellaneous

Free Float
51,638,000
Market Cap
$451.13 million
Optionable
Not Optionable
Beta
0.88
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Richard A. Heyman Ph.D. (Age 66)
    Co-Founder, Independent Chairman & Member of Scientific Advisory Board
    Comp: $93k
  • Dr. Jacob M. Chacko M.B.A. (Age 44)
    M.D., President, CEO & Director
    Comp: $921.32k
  • Mr. Dominic G. Piscitelli CPA (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $636.91k
  • Dr. Pratik S. Multani M.D. (Age 56)
    M.S., Chief Medical Officer
    Comp: $686.88k
  • Dr. Charles L. Sawyers B.A. (Age 64)
    M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Scott W. Lowe Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Lori Sickels Friedman Ph.D. (Age 59)
    Chief Scientific Officer
  • Dr. Christian V. Kuhlen Esq. (Age 50)
    J.D., M.D., General Counsel
  • Mr. Daniel Iazzetti
    VP & Head of People
  • Dr. Edna Chow Maneval (Age 63)
    Senior Vice President of Clinical Development














ORIC Stock Analysis - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings
or view top-rated stocks.

What is ORIC Pharmaceuticals' stock price target for 2024?

7 equities research analysts have issued 12 month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price targets range from $13.00 to $27.00. On average, they anticipate the company's stock price to reach $16.29 in the next year. This suggests a possible upside of 96.9% from the stock's current price.
View analysts price targets for ORIC
or view top-rated stocks among Wall Street analysts.

How have ORIC shares performed in 2023?

ORIC Pharmaceuticals' stock was trading at $5.89 at the start of the year. Since then, ORIC stock has increased by 40.4% and is now trading at $8.27.
View the best growth stocks for 2023 here
.

When is ORIC Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our ORIC earnings forecast
.

How were ORIC Pharmaceuticals' earnings last quarter?

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.02.

What other stocks do shareholders of ORIC Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?

(ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.

Who are ORIC Pharmaceuticals' major shareholders?

ORIC Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Alkeon Capital Management LLC (6.38%), FMR LLC (5.74%), Silverarc Capital Management LLC (2.06%), Euclidean Capital LLC (1.81%), Vivo Capital LLC (1.43%) and Monaco Asset Management SAM (0.71%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller.
View institutional ownership trends
.

How do I buy shares of ORIC Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ORIC) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -